Market Overview:
The global glycated hemoglobin control market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising awareness about glycemic control, and technological advancements in glycated hemoglobin testing devices. Based on type, the global glycated hemoglobin control market is segmented into CRL-1:2mL—1, CRL-2:2mL—1, CRL-1:2mL—3, and CRL-2: 2mL — 3. The largest share of the global glycated hemoglobin control market is held by the CRL- 1: 2 mL — 1 type segment due to its low cost and easy availability. Based on application, the global glycated hemoglobin control market is segmented into hospitals, clinics,, and other applications such as research laboratories and home care settings.
Product Definition:
A glycated hemoglobin test is a blood test that measures the average amount of glucose (sugar) in your blood over the past 2 to 3 months. The results of this test tell you how well your diabetes treatment plan is working.
CRL-1:2mL—1:
CRL-1:2mL is also known as erythropoietin or Erythropoietin Growth Factor (EPGF). It's a glycoprotein hormone that controls the rate of red blood cell production and hence, affects the level of hemoglobin in the body. The normal range for human blood sugar levels is between 70-90 mg/dL.
CRL-2:2mL—1:
CRL-2:2mL is a novel, small volume, ready to use solution that contains Cationic Lipid-based Reagents and it's used for Glycated Hemoglobin (HbA) control. The product works by enhancing the affinity of HbA for the chelating agent and helps in removing excess HbA from circulation. It also prevents newly formed HbS from getting attached to hemoglobin chains.
Application Insights:
The other application segment includes commercial laboratories, home care settings and others. The other applications include hospitals, clinics and others. Glycated hemoglobin control market by application in 2017 is dominated by the hospital segment with a share of over 60% in the global market. This high share is attributable to factors such as presence of a large patient base suffering from GED who require regular monitoring for treatment purposes at hospitals or clinics which drives demand for glycated hemoglobin control tests at these facilities.
Hospitals are also one of the major consumers of blood glucose testing strips due to rising prevalence of diabetes-related diseases across regions coupled with an increasing number of surgeries that require parenteral nutrition has driven demand for these tests within healthcare institutions over recent years.
Regional Analysis:
North America dominated the global glycation control market in 2017. The presence of well-developed healthcare infrastructure and favorable reimbursement policies are some factors responsible for its large share. In addition, the high adoption of advanced technologies and products is also expected to drive this regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to increasing diabetic population coupled with rising healthcare expenditure in developing economies such as China, India, Singapore, Thailand & South Korea. Moreover, economic development has led to an increase in disposable income which will further boost demand for medical treatments; thereby driving this regional market at a significant pace during the forecast years from 2018 to 2030 (Ref).
Key players operating in Asia Pacific include Roche Diagnostics Corporation; Siemens Healthineers AG; Bio-Rad Laboratories Inc.; PerkinElmer Inc.; and Abbott Laboratories (China) Co., Ltd., among others (Ref).
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is primarily because of the changing lifestyle and dietary habits. As a result, there is an increased demand for glycemic control products and services.
- Rising awareness about the benefits of glycemic control: There is a growing awareness among people about the importance of glycemic control in preventing long-term health complications associated with diabetes. This is driving demand for glycation hemoglobin products and services worldwide.
- Technological advancements in hemoglobin testing: There have been significant advancements in hemoglobin testing technologies over the past few years, which has led to improved accuracy and precision in measuring glycated hemoglobin levels. This is benefiting the growth prospects of the glycated hemoglobin control market globally.
Scope Of The Report
Report Attributes
Report Details
Report Title
Glycated Hemoglobin Control Market Research Report
By Type
CRL-1:2mL×1, CRL-2:2mL×1, CRL-1:2mL×3, CRL-2:2mL×3, Other
By Application
Hospitals, Clinics, Other
By Companies
Tosoh, Hitachi, Siemens, Abbott, Canterbury Scientific Ltd., JEOL Ltd., Trinity Biotech, SEKISUI CHEMICAL CO.,LTD, Sysmex Corporation, Randox Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
164
Number of Tables & Figures
115
Customization Available
Yes, the report can be customized as per your need.
Global Glycated Hemoglobin Control Market Report Segments:
The global Glycated Hemoglobin Control market is segmented on the basis of:
Types
CRL-1:2mL×1, CRL-2:2mL×1, CRL-1:2mL×3, CRL-2:2mL×3, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Tosoh
- Hitachi
- Siemens
- Abbott
- Canterbury Scientific Ltd.
- JEOL Ltd.
- Trinity Biotech
- SEKISUI CHEMICAL CO.,LTD
- Sysmex Corporation
- Randox Laboratories
Highlights of The Glycated Hemoglobin Control Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CRL-1:2mL×1
- CRL-2:2mL×1
- CRL-1:2mL×3
- CRL-2:2mL×3
- Other
- By Application:
- Hospitals
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glycated Hemoglobin Control Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glycated hemoglobin control is a medical treatment that helps to lower the level of glycated hemoglobin in the blood. Glycated hemoglobin is a form of blood sugar that has been linked with an increased risk for heart disease, stroke, and other health problems.
Some of the major players in the glycated hemoglobin control market are Tosoh, Hitachi, Siemens, Abbott, Canterbury Scientific Ltd., JEOL Ltd., Trinity Biotech, SEKISUI CHEMICAL CO.,LTD, Sysmex Corporation, Randox Laboratories.
The glycated hemoglobin control market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Glycated Hemoglobin Control Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Glycated Hemoglobin Control Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Glycated Hemoglobin Control Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Glycated Hemoglobin Control Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Glycated Hemoglobin Control Market Size & Forecast, 2018-2028
4.5.1 Glycated Hemoglobin Control Market Size and Y-o-Y Growth
4.5.2 Glycated Hemoglobin Control Market Absolute $ Opportunity
Chapter 5 Global Glycated Hemoglobin Control Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Glycated Hemoglobin Control Market Size Forecast by Type
5.2.1 CRL-1:2mL×1
5.2.2 CRL-2:2mL×1
5.2.3 CRL-1:2mL×3
5.2.4 CRL-2:2mL×3
5.2.5 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Glycated Hemoglobin Control Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Glycated Hemoglobin Control Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Glycated Hemoglobin Control Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Glycated Hemoglobin Control Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Glycated Hemoglobin Control Analysis and Forecast
9.1 Introduction
9.2 North America Glycated Hemoglobin Control Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Glycated Hemoglobin Control Market Size Forecast by Type
9.6.1 CRL-1:2mL×1
9.6.2 CRL-2:2mL×1
9.6.3 CRL-1:2mL×3
9.6.4 CRL-2:2mL×3
9.6.5 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Glycated Hemoglobin Control Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Glycated Hemoglobin Control Analysis and Forecast
10.1 Introduction
10.2 Europe Glycated Hemoglobin Control Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Glycated Hemoglobin Control Market Size Forecast by Type
10.6.1 CRL-1:2mL×1
10.6.2 CRL-2:2mL×1
10.6.3 CRL-1:2mL×3
10.6.4 CRL-2:2mL×3
10.6.5 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Glycated Hemoglobin Control Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Glycated Hemoglobin Control Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Glycated Hemoglobin Control Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Glycated Hemoglobin Control Market Size Forecast by Type
11.6.1 CRL-1:2mL×1
11.6.2 CRL-2:2mL×1
11.6.3 CRL-1:2mL×3
11.6.4 CRL-2:2mL×3
11.6.5 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Glycated Hemoglobin Control Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Glycated Hemoglobin Control Analysis and Forecast
12.1 Introduction
12.2 Latin America Glycated Hemoglobin Control Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Glycated Hemoglobin Control Market Size Forecast by Type
12.6.1 CRL-1:2mL×1
12.6.2 CRL-2:2mL×1
12.6.3 CRL-1:2mL×3
12.6.4 CRL-2:2mL×3
12.6.5 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Glycated Hemoglobin Control Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Glycated Hemoglobin Control Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Glycated Hemoglobin Control Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Glycated Hemoglobin Control Market Size Forecast by Type
13.6.1 CRL-1:2mL×1
13.6.2 CRL-2:2mL×1
13.6.3 CRL-1:2mL×3
13.6.4 CRL-2:2mL×3
13.6.5 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Glycated Hemoglobin Control Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Glycated Hemoglobin Control Market: Competitive Dashboard
14.2 Global Glycated Hemoglobin Control Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Tosoh
14.3.2 Hitachi
14.3.3 Siemens
14.3.4 Abbott
14.3.5 Canterbury Scientific Ltd.
14.3.6 JEOL Ltd.
14.3.7 Trinity Biotech
14.3.8 SEKISUI CHEMICAL CO.,LTD
14.3.9 Sysmex Corporation
14.3.10 Randox Laboratories
